Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMRC Horizon One: Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT06171685Phase 2Active, not recruiting
- Start
- Nov 2024
- Primary completion
- Jul 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of teclistamab in multiple myeloma (MM) (2 arms). Primary endpoint: Objective Response Rate. Started Nov 2024; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06171685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171685.